The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Open accessAbstract
Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and anti-proliferative effects. Their development was facilitated by an improved understanding in myeloma (MM) biology and initiated a profound shift in the therapeutic approach towards MM. Despite the diverse effects of IMiDs in vitro, the relative contribution of each effect towards their ultimate anti-MM activity is still unclear. Based on in vitro data, it appears that anti-proliferative effects and downregulation of crucial cytokines are their most important anti-MM attributes. Although the co-stimulatory effects on T and NK cells have been heralded as a unique and important property of IMiDs towards enhancing anti-MM immune activity, these in vitro effects have yet to be firmly corroborated in vivo. Much is yet to be elucidated regarding the complex interplay of immunomodulatory cytokines that occurs in vivo, which ultimately dictates the net effects of IMiDs in MM—the understanding of which is necessary to facilitate optimal manipulation of these drugs in future MM management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., & Seibert, K. (2000) · PubMed · Cited by 1,401
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
TOWARD AN UNDERSTANDING OF NKT CELL BIOLOGY: Progress and Paradoxes
Kronenberg, M. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115742 · Cited by 1,029
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Chu, Z.-L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., & Ballard, D. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10057 · Cited by 872
Carnaud, C., Lee, D., Donnars, O., Park, S.-H., Beavis, A., Koezuka, Y., & Bendelac, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4647 · Cited by 854
A fresh look at tumor immunosurveillance and immunotherapy
Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001) · Nature Immunology · doi:10.1038/86297 · Cited by 745
Self-citationBeyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Genes and ligands for odorant, vomeronasal and taste receptors
Mombaerts, P. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1365 · Cited by 694
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling
Kreuz, S., Siegmund, D., Scheurich, P., & Wajant, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3964-3973.2001 · Cited by 583
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Tregs and rethinking cancer immunotherapy
Curiel, T. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31202 · Cited by 547
Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
Álvaro, T., Lejeune, M., Salvadó, M. T., Bosch, R., García, J. F., Jaén, J., Banham, A. H., Roncador, G., Montalbán, C., & Piris, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1869 · Cited by 450
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S., et al. (2002) · Blood · doi:10.1182/blood.v100.1.230 · Cited by 442
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
Dhodapkar, M. V., Geller, M. D., Chang, D. H., Shimizu, K., Fujii, S.-I., Dhodapkar, K. M., & Krasovsky, J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021650 · Cited by 425
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., & Anderson, K. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2212 · Cited by 399
Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Galustian, C., Meyer, B., Labarthe, M.-C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0620-4 · Cited by 391
Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D. M., Gibson, J., Ho, P. J., Hart, D., & Joshua, D. (2001) · Blood · doi:10.1182/blood.v98.10.2992 · Cited by 347
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Muller, G. W., Chen, R., Huang, S.-Y., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., & Stirling, D. I. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00250-4 · Cited by 341
Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S. P., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323
Hinson, R. M., Williams, J. A., & Shacter, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4885 · Cited by 302
Beyer, M., Kochanek, M., Giese, T., Endl, E., Weihrauch, M. R., Knolle, P. A., Classen, S., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2005-09-3671 · Cited by 301
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Geitz, H., Handt, S., & Zwingenberger, K. (1996) · Immunopharmacology · doi:10.1016/0162-3109(95)00050-x · Cited by 291
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., et al. (2004) · Blood · doi:10.1182/blood-2003-02-0361 · Cited by 289
Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v89.1.227 · Cited by 272
Dredge, K., Horsfall, R., Robinson, S. P., Zhang, L.-H., Lu, L., Tang, Y., Shirley, M. A., Muller, G., Schafer, P., Stirling, D., et al. (2005) · Microvascular Research · doi:10.1016/j.mvr.2005.01.002 · Cited by 268
Dysfunctional T regulatory cells in multiple myeloma
Prabhala, R. H., Neri, P., Bae, J. E., Tassone, P., Shammas, M. A., Allam, C. K., Daley, J. F., Chauhan, D., Blanchard, E., Thatte, H. S., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3101 · Cited by 239
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells
Urashima, M., Ogata, A., Chauhan, D., Hatziyanni, M., Vidriales, M., Dedera, D., Schlossman, R., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.5.1928.1928 · Cited by 235
Pellagatti, A., Jädersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610477104 · Cited by 233
Trzonkowski, P., Szmit, E., Myśliwska, J., Dobyszuk, A., & Myśliwski, A. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.04.003 · Cited by 223
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
Immunomodulation by thalidomide and thalidomide analogues
Corral, L. G., & Kaplan, G. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i107 · Cited by 202
Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma
Yang, Z.-Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E., & Ansell, S. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1822 · Cited by 190
Schafer, P. H., Gandhi, A. K., Loveland, M. A., Chen, R. S., Man, H.-W., Schnetkamp, P. P. M., Wolbring, G., Govinda, S., Corral, L. G., Payvandi, F., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048496 · Cited by 182
Tai, Y.-T., Li, X.-F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W., Podar, K., Hideshima, T., Chauhan, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1657 · Cited by 167
Natural Killer Cells Produce T Cell–Recruiting Chemokines in Response to Antibody-Coated Tumor Cells
Roda, J. M., Parihar, R., Magro, C., Nuovo, G. J., Tridandapani, S., & Carson, W. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2429 · Cited by 165
Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 162
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O. (2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2006.00692.x · Cited by 161
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Anderson, K. C., & Treon, S. P. (2002) · Blood · doi:10.1182/blood.v99.6.2162 · Cited by 159
Muller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., & Stirling, D. I. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9603328 · Cited by 158
Iyer, C. G. S., Languillon, J., Ramanujam, K., Tarabini-castellani, G., Aguas, J. T. D. L., Lm, B., Uemura, K., Domínguez, M. S. C., & Sundaresan, T. (1971) · Europe PMC (PubMed Central) · Cited by 155
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V. S., Donnenberg, A. D., Ghobrial, I. M., Mapara, M. Y., Stirling, D., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3450 · Cited by 155
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Gupta, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2002) · PubMed · Cited by 155
Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity
Corral, L. G., Muller, G. W., Moreira, A. L., Chen, Y., Wu, M., Stirling, D., & Kaplan, G. (1996) · Molecular Medicine · doi:10.1007/bf03401909 · Cited by 155
Characterization of adhesion molecules on human myeloma cell lines
Uchiyama, H., Barut, B., Chauhan, D., Cannistra, S., & Anderson, K. C. (1992) · Blood · doi:10.1182/blood.v80.9.2306.2306 · Cited by 146
Feyler, S., Lilienfeld‐Toal, M. V., Jarmin, S. J., Marles, L., Rawstron, A. C., Ashcroft, A. J., Owen, R. G., Selby, P. J., & Cook, G. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07530.x · Cited by 146
Corral, L. G., Muller, G. W., Moreira, A. L., Chen, Y., Wu, M., Stirling, D., & Kaplan, G. (1996) · PubMed Central · Cited by 137
Takahashi, A., Kono, K., Ichihara, F., Sugai, H., Fujii, H., & Matsumoto, Y. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0466-8 · Cited by 117
Lapalombella, R., Yu, B., Triantafillou, G., Liu, Q., Butchar, J. P., Lozanski, G., Ramanunni, A., Smith, L. L., Blum, W. G., Andritsos, L. A., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133108 · Cited by 117
NF-??B in the pathogenesis and treatment of multiple myeloma
Li, Z., Chen, H., Campbell, R. A., Bonavida, B., & Berenson, J. R. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328302c7f4 · Cited by 115
Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma
Brimnes, M. K., Svane, I. M., & Johnsen, H. E. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03037.x · Cited by 111
Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production
Costes, V., Portier, M., Lu, Z., Rossi, J., Bataille, R., & Klein, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01101.x · Cited by 88
High Th1/Th2 ratio in patients with multiple myeloma
Ogawara, H., Handa, H., Yamazaki, T., Toda, T., Yoshida, K., Nishimoto, N., Al-ma’Quol, W. H. S., Kaneko, Y., Matsushima, T., Tsukamoto, N., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.06.003 · Cited by 84
Biosynthesis and processing of cathepsin K in cultured human osteoclasts
Rieman, D. J., McClung, H. A., Dodds, R. A., Hwang, S. M., Holmes, M. W. L., James, I. E., Drake, F. H., & Gowen, M. (2001) · Bone · doi:10.1016/s8756-3282(00)00445-2 · Cited by 78
Payvandi, F., Wu, L., Haley, M., Schafer, P. H., Zhang, L., Chen, R. S., Muller, G. W., & Stirling, D. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.09.003 · Cited by 77
Regulatory T-cell development: is Foxp3 the decider?
Curiel, T. J. (2007) · Nature Medicine · doi:10.1038/nm0307-250 · Cited by 57
Wakabayashi, H., Varfaj, F., DeAngelis, J. P., & Fay, P. J. (2008) · Blood · doi:10.1182/blood-2008-02-142158 · Cited by 51
Thalidomide-derived immunomodulatory drugs as therapeutic agents
Galustian, C., Labarthe, M., Bartlett, J. B., & Dalgleish, A. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.12.1963 · Cited by 50
5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis
Price, D. K., Ando, Y., Kruger, E. A., Weiß, M., & Figg, W. D. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200202000-00017 · Cited by 50
Prince, H. M., Mileshkin, L., Roberts, A. W., Ganju, V., Underhill, C. R., Catalano, J. V., Bell, R. H., Seymour, J. F., Westerman, D., Simmons, P. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0213 · Cited by 49
Self-citationFirst thalidomide clinical trial in multiple myeloma: a decade
van Rhee, F., Dhodapkar, M. V., Shaughnessy, J. D., Anaissie, E. J., Siegel, D. S. D., Hoering, A., Zeldis, J. B., Jenkins, B., Singhal, S., Mehta, J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140954 · Cited by 46
Viral antigen‐specific CD8+ T‐cell responses are impaired in multiple myeloma
Maecker‐Kolhoff, B., Anderson, K. S., von Bergwelt‐Baildon, M. S., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04375.x · Cited by 45
Payvandi, F., Wu, L., Naziruddin, S., Haley, M., Parton, A., Schafer, P. H., Chen, R. S., Muller, G. W., Hughes, C. C. W., & Stirling, D. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.604 · Cited by 44
Thalidomide metabolites in mice and patients with multiple myeloma.
Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Muller, G. W., & Ching, L.-M. (2003) · PubMed · Cited by 42
Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease
Akobeng, A. K., & Stokkers, P. C. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007351.pub2 · Cited by 37
Regulatory T Cells and Multiple Myeloma
Joshua, D., Brown, R. D., Ho, P. J., & Gibson, J. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.039 · Cited by 36
Mileshkin, L., Hönemann, D., Gambell, P. C., Trivett, M., Hayakawa, Y., Smyth, M. J., Beshay, V., Ritchie, D., Simmons, P. J., Milner, A., et al. (2007) · Haematologica · doi:10.3324/haematol.11208 · Cited by 36
Self-citationGandhi, V. V., Balakrishnan, K., & Chen, L. S. (2008) · Blood · doi:10.1182/blood-2008-07-170241 · Cited by 30
Zhang, M., Abe, Y., Matsushima, T., Nishimura, J., Nawata, H., & Muta, K. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400015691 · Cited by 25
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 801
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Self-citationChamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Metadata
- Authors
- Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M.
- Venue
- Leukemia
- Published
- 2009-11-12
- Volume
- 24
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2133739087
- Cited by
- 600
- References
- 87
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.